Genetic polymorphisms of bone marrow stromal cell antigen-1 (BST-1/CD157): implications for immune/inflammatory dysfunction in neuropsychiatric disorders

Shigeru Yokoyama

doi:10.3389/fimmu.2023.1197265

Genetic polymorphisms of bone marrow stromal cell antigen-1 (BST-1/CD157): implications for immune/inflammatory dysfunction in neuropsychiatric disorders

Front Immunol. 2023 May 29:14:1197265. doi: 10.3389/fimmu.2023.1197265. eCollection 2023.

Author

Shigeru Yokoyama^{1

2}

Affiliations

¹ Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan.
² Division of Socio-Cognitive-Neuroscience, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Kanazawa, Japan.

Abstract

Bone marrow stromal cell antigen-1 (BST-1/CD157) is an immune/inflammatory regulator that functions as both nicotinamide adenine dinucleotide-metabolizing ectoenzyme and cell-surface signaling receptor. BST-1/CD157 is expressed not only in peripheral tissues, but in the central nervous system (CNS). Although its pathophysiological significance in the CNS is still unclear, clinical genetic studies over a decade have begun revealing relationships between BST-1/CD157 and neuropsychiatric diseases including Parkinson's disease, autism spectrum disorders, sleep disorders, depressive disorders and restless leg syndrome. This review summarizes the accumulating evidence for the involvement of BST-1/CD157 in these disorders.

Keywords: BST-1; CD157; Parkinson’s disease; anxiety; autism spectrum disorder; neuroimmune dysfunction; single-nucleotide polymorphism.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Autism Spectrum Disorder*
Central Nervous System
Humans
Immune System Diseases*
Mesenchymal Stem Cells*
Polymorphism, Genetic

Grants and funding

Our studies cited in this report was supported in part by the Collaborative Research Program of the Collaborative Research Network for Asian Children with Developmental Disorders: MEXT Policy Initiative FY2021, under joint research conducted through the initiative.